Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Triple Negative Breast Cancer|Neoadjuvant Chemotherapy|Pembrolizumab|Tumor Microenvironment
Interventions: GENETIC: Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Sponsor: Samsung Medical Center